Monthly Archives: September 2011

Theostan-CR Tablets

Company: Ranbaxy Laboratories Ltd. Generic Drug: Theophylline. Indication: Bronchial asthma and chronic bronchitis. Contraindication: Hypersensitivity to any of the component, porphyria. Dosage & Administration: Available as tablets for oral use. Dosage as directed by physician. Special Precautions: Special precautions are … Continue reading

Posted in Asthma Medications | Leave a comment

Theoped

Company: Cipla Ltd. Generic Drug: Theophylline Indication: Bronchial asthma and chronic bronchitis. Contraindication: Hypersensitivity to any of the component, porphyria. Dosage & Administration: Available as liquid suspension for oral use. Dosage as directed by physician. Special Precautions: Special precautions are … Continue reading

Posted in Asthma Medications | Tagged | Leave a comment

Theobid / Theoday

Company: Cipla Ltd. Generic Drug: Theophylline. Indication: Bronchial asthma and chronic bronchitis. Contraindication: Hypersensitivity to any of the component, porphyria. Dosage & Administration: Available as tablets for oral use. Dosage as directed by physician. Special Precautions: Special precautions are necessary … Continue reading

Posted in Asthma Medications | Tagged | Leave a comment

Theo PA Tablets

Company: Glaxo India Ltd. Generic Drug: Theophylline. Indication: Bronchial asthma and chronic bronchitis. Contraindication: Hypersensitivity to any of the component, porphyria. Dosage & Administration: Available as tablets for oral use. Dosage as directed by physician. Special Precautions: Special precautions are … Continue reading

Posted in Asthma Medications | Leave a comment

Theo-Asthalin

Company: Cipla Ltd. Generic Drug: Salbutamol + Theophylline Indication: Asthma, emphysema and chronic bronchitis. Contraindication: Hypersensitivity to any of the component. It is also contraindicated to the patients with active peptic ulcer disease. Dosage & Administration: Available as tablets and … Continue reading

Posted in Asthma Medications | Tagged | 2 Comments